SCHEMBL24252629

SCHEMBL24252629

COc1ccc(B(O)O)cc1-c1cnc2c(N)cnnc2c1

nearest known ligand 0.42

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 15/20 0.42
GAK O14976 2/20 0.35
KDR P35968 1/20 0.34
NTRK1 P04629 1/20 0.33
PDGFRB P09619 1/20 0.33
PDGFRA P16234 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30451479 1.00 PDE10A (0.42) PDE10AGAKKDRNTRK1PDGFRB
SCHEMBL26771357 0.92 PDE10A (0.41) PDE10AGAK
SCHEMBL30467809 0.83 PDE10A (0.46) PDE10A
SCHEMBL24252260 0.83 PDE10A (0.46) PDE10A
SCHEMBL24252346 0.81 PDE10A (0.37) PDE10A
SCHEMBL30451296 0.81 PDE10A (0.37) PDE10A
SCHEMBL24252274 0.80 PDE10A (0.36) PDE10APDGFRBPDGFRA
SCHEMBL31753947 0.80 PDE10A (0.36) PDE10APDGFRBPDGFRA
SCHEMBL24252743 0.77 PLG (0.41) KDRNTRK1PDGFRBPDGFRA
SCHEMBL30467655 0.76 PDE10A (0.38) PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 PDE10A 1950/4885GAK 3323/4885KDR 3397/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 PDE10A 1950/4885GAK 3323/4885KDR 3397/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 PDE10A 2158/4885GAK 1377/4885KDR 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.